Less than a year after the global emergence of the coronavirus SARS-CoV-2, a novel
vaccine platform based on mRNA technology was introduced to the market. Globally, around …

Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum
accounting for the majority of malaria, and P. vivax being a second important cause …

Monoclonal antibodies are being developed as therapeutics to complement drugs and
vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies …

IgG3 comprises only a minor fraction of IgG and has remained relatively understudied until
recent years. Key physiochemical characteristics of IgG3 include an elongated hinge region …

Antibodies play major roles in immunity to malaria; however, a limited understanding of
mechanisms mediating protection is a major barrier to vaccine development. We have …

Background An understanding of the mechanisms mediating protective immunity against
malaria in humans is currently lacking, but critically important to advance the development of …

Background One of the criteria to objectively prioritize merozoite antigens for malaria
vaccine development is the demonstration that naturally acquired antibodies are associated …

The development of effective malaria vaccines and immune biomarkers of malaria is a high
priority for malaria control and elimination. Ags expressed by merozoites of Plasmodium …

Individuals in areas of Plasmodium falciparum endemicity develop immunity to malaria after
repeated exposure. Knowledge of the acquisition and nature of protective immune …

An effective blood-stage vaccine against Plasmodium falciparum remains a research
priority, but the number of antigens that have been translated into multicomponent vaccines …